Blonanserin ameliorates phencyclidine-induced visual-recognition memory deficits: the complex mechanism of blonanserin action involving D₃-5-HT₂A and D₁-NMDA receptors in the mPFC

Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology
Hirotake HidaYukihiro Noda


Blonanserin differs from currently used serotonin 5-HT₂A/dopamine-D₂ receptor antagonists in that it exhibits higher affinity for dopamine-D₂/₃ receptors than for serotonin 5-HT₂A receptors. We investigated the involvement of dopamine-D₃ receptors in the effects of blonanserin on cognitive impairment in an animal model of schizophrenia. We also sought to elucidate the molecular mechanism underlying this involvement. Blonanserin, as well as olanzapine, significantly ameliorated phencyclidine (PCP)-induced impairment of visual-recognition memory, as demonstrated by the novel-object recognition test (NORT) and increased extracellular dopamine levels in the medial prefrontal cortex (mPFC). With blonanserin, both of these effects were antagonized by DOI (a serotonin 5-HT₂A receptor agonist) and 7-OH-DPAT (a dopamine-D₃ receptor agonist), whereas the effects of olanzapine were antagonized by DOI but not by 7-OH-DPAT. The ameliorating effect was also antagonized by SCH23390 (a dopamine-D₁ receptor antagonist) and H-89 (a protein kinase A (PKA) inhibitor). Blonanserin significantly remediated the decrease in phosphorylation levels of PKA at Thr(197) and of NR1 (an essential subunit of N-methyl-D-aspartate (NMDA) receptors) at Ser(897) ...Continue Reading


Sep 1, 1992·Proceedings of the National Academy of Sciences of the United States of America·D LévesqueP Sokoloff
Oct 1, 1991·The American Journal of Psychiatry·Daniel C Javitt, S R Zukin
Feb 22, 1991·Science·T Sawaguchi, Patricia S Goldman-Rakic
Jan 1, 1994·Acta Psychiatrica Scandinavica. Supplementum·W D SpauldingD Storzbach
Sep 1, 1996·Synapse·B LevantC M Selkirk
Jan 14, 1999·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·E V Gurevich, J N Joyce
Feb 22, 2001·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Akihiro NodaToshitaka Nabeshima
Jun 25, 2002·Trends in Neurosciences·Verity J Brown, Eric M Bowman
Dec 24, 2002·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Laurel M PritchardNeil M Richtand
Mar 1, 1965·Journal of Medicinal Chemistry·V H MADDOXR F PARCELL
Oct 31, 2003·The New England Journal of Medicine·Robert Freedman
Dec 4, 2003·Progress in Neuro-psychopharmacology & Biological Psychiatry·H Y MeltzerJunji Ichikawa
Jun 4, 2004·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Kuei Y Tseng, Patricio O'Donnell
Jun 19, 2004·Psychopharmacology·Stacy A CastnerGraham V Williams
Jun 29, 2004·Clinical Therapeutics·Anthony DeLeonM Lynn Crismon
Jan 22, 2005·Current Opinion in Pharmacology·Brian J MorrisJudith A Pratt
Jul 14, 2007·European Journal of Pharmacology·István Gyertyán, Katalin Sághy
Feb 3, 2009·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Maria Sol KruseThérèse M Jay
May 13, 2010·Pharmacology, Biochemistry, and Behavior·Yukihiro OhnoSaki Shimizu
Oct 28, 2011·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·David J G WatsonKevin C F Fone
Jan 27, 2012·Human Psychopharmacology·Tomomi TenjinNoboru Yamaguchi
Oct 3, 2012·Handbook of Experimental Pharmacology·Gerhard Gross, Karla Drescher
Jun 15, 2013·Neuropsychiatric Disease and Treatment·Tomomi TenjinNoboru Yamaguchi
Jun 25, 2013·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Shinichiro NakajimaAriel Graff-Guerrero
Jul 17, 2013·Asia-Pacific Psychiatry : Official Journal of the Pacific Rim College of Psychiatrists·Sakae TakahashiMakoto Uchiyama


Sep 13, 2015·Pharmacology, Biochemistry, and Behavior·Ayaka TataraYukihiro Ohno
Sep 24, 2015·The International Journal of Neuropsychopharmacology·Luca PosaNicolas Marie
Jun 28, 2016·Pharmacology & Therapeutics·G M LeggioFilippo Drago
Apr 17, 2020·Archives of Toxicology·Kwang-Hyun HurChoon-Gon Jang

Related Concepts

4-iodo-2,5-dimethoxyphenylisopropylamine, 131I-labeled
7-hydroxy-2-N, N-dipropylaminotetralin, (S)-isomer

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here